Pionyr’s Phase 1a Study of TREM1-targeting Antibody PY159 Featured at ASCO
25 May 2023 //
BUSINESSWIRE
Gilead passes on fully acquiring Pionyr, as eyes now turn to Tizona
23 Mar 2023 //
ENDPTS
Pionyr Immunotherapeutics’ MARCO-targeting Antibody Program, PY265
07 Nov 2022 //
BUSINESSWIRE
Pionyr doses first subject in Phase Ib cancer antibody trial
21 Sep 2022 //
CLINICALTRIALSARENA
Pionyr to Present on Myeloid Tuning Platform and TREM1 Targeting Ab Program
16 Jun 2022 //
BUSINESSWIRE